Genomic analyses identify gene candidates for acquired irinotecan resistance in melanoma cells

International Journal of Oncology

Volumn 32, Issue 6, 2008, Pages 1343-1349

  Gao, Kai ^a   Lockwood, William W ^b   Li, Jun ^a   Lam, Wan ^b   Li, Gang ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

Array CGH; Drug resistance; Irinotecan; Melanoma; Topoisomerase

Indexed keywords

CENTROMERE PROTEIN B; CHECKPOINT KINASE 1; CHROMOSOME PROTEIN; DNA METHYLTRANSFERASE 3B; DNA TOPOISOMERASE; DNA TOPOISOMERASE IIIB; GLUTATHIONE PEROXIDASE 2; IRINOTECAN; MESSENGER RNA; MINICHROMOSOME MAINTENANCE PROTEIN 5; PROTEIN ABCD1; PROTEIN ABCD4; PROTEIN ATP6V1D; PROTEIN CCDN1; PROTEIN CSTZ1; PROTEIN H2AFX; PROTEIN MLH3; PROTEIN NGB; PROTEIN P53; PROTEIN RDH11; PROTEIN SLC10A6; PROTEIN ZADH1; PROTEIN ZW10; RAD51 LIGAND; REACTIVE OXYGEN METABOLITE; SPO11 PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; TUMOR MARKER;

AMPLICON; ARTICLE; CANCER RESISTANCE; CHROMOSOMAL INSTABILITY; CHROMOSOME 14Q; CHROMOSOME ABERRATION; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DNA REPAIR; GENE IDENTIFICATION; GENE LOCUS; GENE LOSS; GENETIC ANALYSIS; GENETIC GAIN; GENOMIC INSTABILITY; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; CELL CULTURE; CHROMOSOME 14; COMPARATIVE STUDY; DNA MICROARRAY; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; NUCLEIC ACID HYBRIDIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CHROMOSOMES, HUMAN, PAIR 14; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 48149100988     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo_32_6_1343     Document Type: Article

References (27)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007.
2. Eigentler TK, Caroli UM, Radny P and Garbe C: Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 4: 748-759, 2003.
3. Daud A, Valkov N, Centeno B, et al: Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study. Clin Cancer Res 11: 3009-3016, 2005.
4. Xu Y and Villalona-Calero MA: Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol 13: 1841-1851, 2002.
5. Hsiang YH, Hertzberg R, Hecht S and Liu LF: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260: 14873-14878, 1985.
6. Tsao YP, D'Arpa P and Liu LF: The involvement of active DNA synthesis in camptothecin-induced G2 arrest: altered regulation of p34cdc2/cyclin B. Cancer Res 52: 1823-1829, 1992.
7. Huang CC, Han CS, Yue XF, et al: Cytotoxicity and sister chromatid exchanges induced in vitro by six anticancer drugs developed in the People's Republic of China. J Natl Cancer Inst 71: 841-847, 1983.
8. Nelson WG and Kastan MB: DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 14: 1815-1823, 1994.
9. Li G, Bush JA and Ho VC: p53-dependent apoptosis in melanoma cells after treatment with camptothecin. J Invest Dermatol 114: 514-519, 2000.
10. Gao K, Dai DL, Martinka M and Li G: Prognostic significance of nuclear factor-{kappa}B p105/p50 in human melanoma and its role in cell migration. Cancer Res 66: 8382-8388, 2006.
11. Li G, Tang L, Zhou X, Tron V and Ho V: Chemotherapy-induced apoptosis in melanoma cells is p53 dependent. Melanoma Res 8: 17-23, 1998.
12. Lockwood WW, Coe BP, Williams AC, MacAulay C and Lam WL: Whole genome tiling path array CGH analysis of segmental copy number alterations in cervical cancer cell lines. Int J Cancer 120: 436-443, 2007.
13. Costelloe T, Fitzgerald J, Murphy NJ, Flaus A and Lowndes NF: Chromatin modulation and the DNA damage response. Exp Cell Res 312: 2677-2686, 2006.
14. Luczak MW and Jagodzinski PP: The role of DNA methylation in cancer development. Folia Histochem Cytobiol 44: 143-154, 2006.
15. Huang Y, Anderle P, Bussey KJ, et al: Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res 64: 4294-4301, 2004.
16. Zhou Y, Hileman EO, Plunkett W, Keating MJ and Huang P: Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood 101: 4098-4104, 2003.
17. Kong Q, Beel JA and Lillehei KO: A threshold concept for cancer therapy. Med Hypotheses 55: 29-35, 2000.
18. Huang P, Feng L, Oldham EA, Keating MJ and Plunkett W: Superoxide dismutase as a target for the selective killing of cancer cells. Nature 407: 390-395, 2000.
19. Snijders AM, Fridlyand J, Mans DA, et al: Shaping of tumor and drug-resistant genomes by instability and selection. Oncogene 22: 4370-4379, 2003.
20. Swanton C, Tomlinson I and Downward J: Chromosomal instability, colorectal cancer and taxane resistance. Cell Cycle 5: 818-823, 2006.
21. Deptala A, Li X, Bedner E, et al: Differences in induction of p53, p21WAF1 and apoptosis in relation to cell cycle phase of MCF-7 cells treated with camptothecin. Int J Oncol 15: 861-871, 1999.
22. Maude SL and Enders GH: Cdk inhibition in human cells compromises chkl function and activates a DNA damage response. Cancer Res 65: 780-786, 2005.
23. Fanton CP, Rowe MW, Moler EJ, et al: Development of a screening assay for surrogate markers of CHK1 inhibitor-induced cell cycle release. J Biomol Screen 11: 792-806, 2006.
24. Furuta T, Takemura H, Liao ZY, et al: Phosphorylation of histone H2AX and activation of Mre11, Rad50 and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J Biol Chem 278: 20303-20312, 2003.
25. Bogliolo M, Lyakhovich A, Callen E, et al: Historic H2AX and Fanconi anemia FANCD2 function in the same pathway to maintain chromosome stability. EMBO J 26: 1340-1351, 2007.
26. Okano M, Bell DW, Haber DA and Li E: DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99: 247-257, 1999.
27. Ueda Y, Okano M, Williams C, et al: Roles for Dnmt3b in mammalian development: a mouse model for the ICF syndrome. Development 133: 1183-1192, 2006.